PMID- 28034979
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20180912
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 18
IP  - 2
DP  - 2017 Feb 1
TI  - Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 374-385
LID - 10.1093/pm/pnw262 [doi]
AB  - OBJECTIVES: To evaluate the efficacy and safety of tanezumab for management of 
      osteoarthritis (OA) knee and hip pain. METHODS: Articles about management of OA 
      knee and hip pains by tanezumab were systematically searched in PubMed, EBSCO, 
      EMBASE, ScienceDirect, Web of Science, OVID, and Cochrane Library from the 
      available date of inception until January 2016. Randomized controlled trials 
      (RCTs) comparing the efficacy and safety of tanezumab with placebo/active 
      comparator for management of OA knee and hip pains were included, and those with 
      confounding conditions were excluded. Study quality was assessed using the Jadad 
      five-point score. Finally, a meta-analysis of all eligible RCTs was performed on 
      Review Manager 5.3 and STATA 12.0. RESULTS: Nine studies with 10 RCTs that 
      enrolled 7,665 patients were included. The reductions in pain intensity are 
      significantly different between tanezumab-treated patients and placebo-treated 
      patients (5,879 patients, mean difference [MD] = -0.98, 95% confidence interval 
      [CI] = -1.18- -0.79). Both functional improvement (6,078 patients, MD = -1.10, 
      95% CI = -1.28- -0.92) and Patient's Global Assessment (PGA; 5,366 patients, MD = 
      -0.27, 95% CI = -0.34- -0.20) are significantly different. There are 
      significantly more discontinued patients due to adverse events (AEs) after 
      treatment with tanezumab (6,537 patients, risk ratio = 1.62, 95% CI = 1.29-2.03). 
      However, differences in serious AEs are not significant. Moreover, 
      tanezumab-treated patients suffer from significantly more paraesthesia, 
      arthralgia, hypoaesthesia, and peripheral edema. CONCLUSIONS: Tanezumab vs 
      placebo provides superior pain relief and improvement in physical function and 
      PGA in knee and hip osteoarthritis patients and is generally well tolerated with 
      acceptable AEs. Low-dose tanezumab (10 or 25 microg/kg and 2.5 mg) provides similar 
      effectiveness in reducing pain and improving function and is associated with 
      fewer AEs. The long-term safety of tanezumab on osteoarthritis knee and hip pain 
      needs further investigation.
CI  - (c) 2016 American Academy of Pain Medicine. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com
FAU - Chen, Junyuan
AU  - Chen J
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Li, Jieruo
AU  - Li J
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Li, Ruobin
AU  - Li R
AD  - Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Wang, Huajun
AU  - Wang H
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Yang, Jie
AU  - Yang J
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Xu, Jichun
AU  - Xu J
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
FAU - Zha, Zhengang
AU  - Zha Z
AD  - Department of Bone and Joint Surgery, The First Affiliated Hospital of Jinan 
      University, Guangzhou, China
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
RN  - 0 (Analgesics)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EQL0E9GCX1 (tanezumab)
SB  - IM
MH  - Analgesics/administration & dosage/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Arthralgia/*drug therapy/*epidemiology
MH  - Comorbidity
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/prevention & 
      control
MH  - Hip Joint/drug effects
MH  - Humans
MH  - Knee Joint/drug effects
MH  - Male
MH  - Osteoarthritis, Hip/drug therapy/*epidemiology
MH  - Osteoarthritis, Knee/drug therapy/*epidemiology
MH  - Pain Measurement/drug effects/statistics & numerical data
MH  - Prevalence
MH  - Randomized Controlled Trials as Topic/*statistics & numerical data
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Meta-Analysis
OT  - Nerve Growth Factor
OT  - Osteoarthritis
OT  - Randomized Controlled Trials
OT  -  Tanezumab
EDAT- 2016/12/31 06:00
MHDA- 2017/12/27 06:00
CRDT- 2016/12/31 06:00
PHST- 2016/12/31 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2016/12/31 06:00 [entrez]
AID - pnw262 [pii]
AID - 10.1093/pm/pnw262 [doi]
PST - ppublish
SO  - Pain Med. 2017 Feb 1;18(2):374-385. doi: 10.1093/pm/pnw262.